Compare Cronos Group Inc (CRON) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs Marsh & McLennan Companies, Inc. — how do they compare? Cronos Group Inc trades at $3.24 (market cap $1.18B), while Marsh & McLennan Companies, Inc. trades at $176.51 (market cap $84.31B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 71.4× Cronos Group Inc's market cap, and Marsh & McLennan Companies, Inc. pays a 2.24% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and Marsh & McLennan Companies, Inc. for 109 Days on average.
| CRON | MRSH | |
|---|---|---|
Market Cap | $1.18B | $84.31B |
Volume | 968,037 | 3,948,947 |
Sector | Health | Financials |
52-Week High | $3.55 | $207.02 |
52-Week Low | $2.30 | $157.32 |
Typical Hold Time | 22 Days | 109 Days |
Enterprise Value | $387.62M | $104.99B |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.24, down 1.37% today amid a bearish technical signal. Recent quarterly earnings show beats in Q1 and Q2 2026, with revenue growth from $118M in 2024 to $147M in 2025. The company reported a net loss of $9.45M in 2025 but projects a profit of $70M for 2026. Analyst sentiment is mixed with a 20% buy rating. News highlights focus on international expansion and a recent Investor Day outlining growth strategies.
Outlook is cautiously optimistic given projected profitability in 2026 and strong cash reserves, but risks include sustained negative cash flow and competitive pressures. The stock's valuation metrics like P/E of 16.95 and P/S of 6.84 suggest moderate pricing relative to peers, though high EV/EBITDA of 43 indicates premium expectations.
Marsh (MRSH) trades at $173.66, up 1.11% today, with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with consistent revenue growth from $20.7B in 2022 to $27.0B in 2025, and net income reaching $4.16B. Recent acquisition of Accel Holdings (October 2026) enhances its insurance advisory footprint. Valuation metrics include a P/E of 21.2 and ROE of 25.72%, indicating efficient capital use. Cash flow remains positive with $486M net inflow in 2025.
Outlook is cautiously optimistic with a consensus price target of $202.71 (17% upside), though 65% of analysts rate Hold. Risks include rising debt-to-asset ratio (35.43% in 2024) and potential margin pressure as net income margin dips to 14.24% in 2026. The stock's proximity to resistance at $174 requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
